AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $296M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$296M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 3 added, 0 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 30- Open
- $362.51
- 52-wk high
- $385.22
- High
- $365.00
- 52-wk low
- $253.95
- Low
- $358.51
- Prev close
- $365.27
- Mkt cap
- $41.32B
- P/E
- 65.5x
- Volume
- 377.2K
- Fwd P/E
- 35.2x
- Beta
- 0.52
- P/S
- 6.7x
- P/B
- 8.0x
- Profit margin
- +10.7%
- Op margin
- +19.1%
- ROE
- +14.7%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about ONC filings
Are insiders buying or selling BeiGene, Ltd. (ONC) stock?
Net selling: insiders sold $296M and bought $0 of ONC stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. $295.3M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Oyler, John (Chief Executive Officer), who sold $293.5M. The latest filing was on Sep 3, 2026.
Which members of Congress have traded ONC recently?
None. No member of Congress disclosed a ONC trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this ONC smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (3)
- MI
Millennium
$94.0M
added
- TS
Two Sigma
$71.7M
added
- JC
JPMorgan Chase
$32.6M
added
What insiders are doing
How top traders are positioned
No tracked top-trader positions in ONC right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 46.4% above what analysts expected.
Earnings per share
$1.40 expected
Reports Nov 5, 2026, in 35 days
Estimates as of Oct 1, 2026
EPS expected
$1.56 to $2.11
Revenue expected
12 analysts
Last 30 days
Analysts raising estimates
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.41B | $1.50B | $1.51B | $1.71B |
| Cost of what it sold | $196.5M | $142.4M | $167.2M | $174.5M |
| Gross profit | $1.22B | $1.36B | $1.35B | $1.53B |
| What it spent | ||||
| Research and development | $523.7M | $615.4M | $541.2M | $612.3M |
| Sales and admin | $529.0M | $555.3M | $555.1M | $593.2M |
| Total operating expenses | $1.05B | $1.17B | $1.10B | $1.21B |
| What was left | ||||
| Operating profit | $163.1M | $185.0M | $249.9M | $325.0M |
| Interest on debt | — | $58.2M | $32.9M | $39.7M |
| Profit before tax | $147.2M | $149.2M | $259.2M | $312.5M |
| Tax | $22.3M | $82.7M | $31.9M | $75.5M |
| Net profit | $124.8M | $66.5M | $227.4M | $237.0M |
| EBITDA | $184.4M | $249.0M | $333.2M | $392.7M |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
80 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage leans bullish
BeOne Medicines (ONC) Rebrand Puts Its Growth Story In Focus On A Higher Fair Value
BullishSep 26BeiGene stock gains 2.16 percent as biotech shares rise
NeutralSep 23BeiGene stock holds steady as investors digest recent quarterly losses
NeutralSep 20
Macro
23 macro signals shaping ONC right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results